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The marketing authorisation of a new medicine is granted on the basis of a favor-
able benefit-risk balance for its target population and indication. However, not all
risks will have been identified at the time when an initial authorisation is sought
and many of the risks associated with the use of a medicinal product will only be
discovered/fully characterised when the medicine is widely used in everyday med-
ical practice. A full HTA should provide for an evaluation of adverse drug reactions
(ADR) including those identified during long term follow- up or which are rare. In
addition to knowledge of risks, a relevant consideration for both individual pa-
tients and policy makers is the performance of risk minimization measures (RMM)
in everyday medical practice. The new European pharmacovigilance legislation
embeds the RMP as a key tool in proactive pharmacovigilance. The RMP, as the
documented set of pharmacovigilance activities and interventions designed to
identify, characterise, and prevent/minimise risks associated with exposure to a
medicine, may include specific RMM. RMM should be shown to achieve the desired
effect of reducing the burden of ADR and optimising health outcomes. Implemen-
tation of RMM may involve a substantial investment of resources and their perfor-
mance in health care systems should be assessed. In case a RMM proves ineffective,
alternative interventions must be identified implemented. We introduce an ap-
proach to evaluating the effectiveness of RMM that builds on the assessment of two
distinct levels of evidence. The evaluation of the effectiveness of RMM should
differentiate between the actual implementation of the RMM, and the attainment
of its final objective(s). If the RMM is unsuccessful, this strategy will help to ascer-
tain whether the intervention was inherently ineffective or badly delivered. The
assessment requires research encompassing analysis of implementation (process
indicators), and traditional epidemiological research addressing the attainment
(final outcome indicators) of RMM.
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Transforming the provision of health care involves collaboration and change on
many levels. Too often health care delivery decisions are made without consider-
ing the complex and dynamic nature of the health system. Approaching these
problems from a systems thinking perspective integrates these traits and encour-
ages long term thinking about solutions. Despite being widely used in other disci-
plines, only recently has systems analysis started to play a larger role in transform-
ing health care provision. The purpose of this work is to outline how systems
analysis tools can bridge multiple levels of health care to make more informed
decisions. The aforementioned will be illustrated using a Canadian case study.
Currently, a provincial strategy to diagnose and treat epilepsy in adults and chil-
dren in Ontario is being examined. The organization of epilepsy specific care cen-
tres (ESCC) into district and regional services is being recommended which will
modify current practice patterns and access to care. Subsequently, any changes in
delivery will have an impact on referral rates and patterns as well as resource
utilization (i.e. beds, staff, and diagnostic tests). The use of systems analysis tools
can bring insight into how the inter-relationship between ESCCs can be modeled
and how access to care will be affected and aid in capacity planning (i.e. resources
and costs).System changes can be graphically illustrated and quantified using the
systems analysis tool discrete event simulation. Mapping the clinical pathways
and patient flow of epileptic patients through the current system, a simulation
model was developed to help inform the planning process. This was useful in
understanding how the system might respond and in identifying potential bottle-
necks or where resources may be limited. Using discrete event simulation facili-
tated the ability to take on multiple perspectives by conducting analyses at multi-
ple institutional levels (i.e. government, hospital and health care practitioner).
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Since the introduction of AMNOG in January 2011, manufacturers in Germany are
required to submit a “benefit dossier” and show additional benefit in relation to a
so-called appropriate comparative therapy to the Federal Joint Committee for every
NCE in order to gain access to price negotiations. If an additional benefit is shown,
the new reimbursed price will be a surplus on the reimbursed comparator price.
Market access in Germany changed significantly due to AMNOG and requires early
preparation, an interdisciplinary approach and clearly defined internal processes.
Market access strategies and processes have to be reviewed in light of the new
framework and adapted in order to optimize the chance to be successful in the
AMNOG process. Preparation for AMNOG should start as early as in the planning of
clinical studies to implement the right questions into the study and not to rely on
surrogate drivers. The FJC will respond best to data providing the most credible
scientific clinical evidence. Building RCTs powered to capture such information
does present important issues for pharmaceutical companies to address. Early
planning of clinical studies should be part of an early strategy development for the
NCE that can be informed by early phase modeling of the likely outcome of the
benefit assessment. Early identification of the patient groups that are most likely to
benefit is vital in order to plan for patient (sub-) populations big enough to achieve
statistical significant results and positive outcomes in the AMNOG process. An
interdisciplinary approach is required at a stage in the product development where
there are no common processes and communication paths established between
headquarter and affiliates. A best practice approach requires a well defined process
including road maps and checklists per stage of product development in form of
standard operating procedures in order to optimize market access.
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Public policies/interventions impact on many areas of activity including areas be-
yond the main focus of them ; the costs and (dis)benefits falling on other areas of
the economy, government and/or private sector, and different individuals. How-
ever, there is no consensus on the appropriate way to analyse such policies/inter-
ventions to decide which are beneficial and should be implemented. One form of
economic evaluation, cost-effectiveness analysis, has been widely used to inform
decisions about policies/interventions which affect only a single sector where
there is a single agreed output (as in most health care evaluations), however, its use
for evaluating interventions with multi-sector impacts is limited. Cost-benefit
analysis (CBA), another form of economic evaluation, based on welfarism, has been
proposed as a method which allows the evaluation of policies/interventions where
costs and benefits fall on several sectors, by aggregating costs and benefits into a
given numeraire, normally consumption. However, a key weakness of CBA is it fails
to acknowledge the relevance of sectors’ budget constraints. This despite the pro-
cess by which budget constraints are set being viewed as having (democratic)
legitimacy. We consider how decisions on policies/interventions with multi-sec-
toral impacts could most appropriately be informed by economic evaluation. Two
options are considered: first, where there is an implied or explicit social welfare
function (which could be based on welfarist or extra-welfarist principles); and
second, a societal decision making approach. We aim to demonstrate that trade-
offs are inevitable and have to be made, but budget constraints cannot be ignored
and shadow prices on budget constraints are central no matter which approach is
accepted. We also consider whether compensation payments between ‘losing’ and
‘gaining’ sectors are a potential means of understanding the net benefit associated
with policies with multi-sectoral effects, and whether it is possible, necessary or
even appropriate in practice to make such payments.
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That the world faces an epidemic of chronic diseases is unmistakable. Chronic
diseases represent 63% of all deaths worldwide. Against the background of demo-
graphic aging, the prevalence of comorbidity or multi-morbidity is as high as 60%
among individuals aged 55 to 74 years. In the context of financial crunch wrought
by the financial crisis, the financial and non-financial burden of chronic diseases
make their management a priority concern globally. Primary care plays a critical
role in dealing with this epidemic. To harness the full potential of primary care,
however, the way it is organized needs transformation. At present 1) primary care
is still organized around the primary care physician even as the shortage of pri-
mary care physician is worsening and is unlikely to improve in the immediate
future; 2) models of care for the chronically ill are directed to the management of
each disease separately, and despite its attribute of continuity, comprehensiveness
and patient-centeredness; 3) fails to harness the contribution of patient self-man-
agement even as role of patient involvement in their health and health care is
recognized; and 4) and overcome the barriers resulting from the structure of the
health care system. These challenges are true for primary care in low and middle-
income settings and high-income settings. A global framework for the transforma-
tion of primary care, consequently, offers promise to every health care system. The
critical elements of such involve 1) the development of primary care teams that
include physician services extenders such as primary care physicians or nurse
practitioners; 2) that will deal with the health needs of the population – rather than
the those of the individual patient; 3) by way of engaging chronically ill patients in
co-managing their condition; 4) using ehealth technologies and point-of-care-test-
ing facilities.
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To successfully support health care decision-making, cost-effectiveness analysis
(CEA) must consider and synthesise all (relevant) available evidence relating to the
clinical effectiveness, health-related quality of life (HRQoL) and costs of the health
technologies under scrutiny. Evidence based medicine tells us that statistical evi-
dence synthesis of multiple individual patient level data (IPD) sources (e.g. IPD
meta-analysis and its extensions) is the gold standard for deriving relative treat-
ment effect estimates, one of the key parameters in any cost-effectiveness model.
Unfortunately the evidence base available to the cost-effectiveness modeller is
often multifaceted and fragmented, comprising a mix of aggregate (AD, or sum-
mary level) and individual patient level data. This scenario poses a series of meth-
odological issues and it is not uncommon for the analyst to end up collapsing the
IPD into AD, with consequent loss of information, for use in a standard evidence
synthesis model (e.g. meta analysis or mixed treatment comparison of AD). Such a
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shortcut though impairs the analysis in many different ways, limiting our full
understanding of the phenomenon being modelled and ultimately our ability to
accurately assess ‘value for money’ beyond the simple ‘average’. This paper ex-
plores the value of access to individual patient data for cost-effectiveness model-
ling, structuring the discussion of the topic around three interrelated questions.
First, what benefits can access to IPD bring to cost-effectiveness modelling? Sec-
ond, what are the challenges for the simultaneous statistically synthesis of AD plus
IPD to derive input parameters for a cost-effectiveness model? Third, what is the
value of access to IPD compared to AD for cost-effectiveness modelling? Using two
different case studies, the above questions will be addressed and discussed in the
context of the debate around CEA of individualised treatment decisions.
DISEASE-SPECIFIC STUDIES
GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies
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THE EFFECTIVENESS AND TOLERABILITY OF COMBINED TREATMENT WITH
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OF PATIENTS WITH CHRONIC HEPATITIS C: RESULTS BASED ON THE
NATIONWIDE HEPATITIS REGISTRY IN JAPAN
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OBJECTIVES: When comparing combined therapy with peginterferon alpha-2a or
alpha-2b and ribavirin to treat chronic hepatitis C (CHC), the results of clinical
trials, observational studies, and meta-analyses have been inconsistent. Their ef-
fectiveness and tolerability were investigated using the nationwide database of
chronic hepatitis patients who received interferon therapy in Japan. METHODS:
The proportion with a sustained virologic response (SVR) and the dropout rate due
to adverse events (AEs) were compared between alpha-2a and alpha-2b. All pa-
tients also received ribavirin. Multivariate logistic regression was conducted with
adjustment for age, sex, platelet counts, ALT, viral load, genotype, and whether the
patient was treatment-naïve, which are associated with effectiveness and
tolerability. RESULTS: By December 2011, the database included 7820 patients. CHC
patients treated with either alpha-2a (n1737) or alpha-2b (n4495) were analyzed.
The mean (SD) age was 58.1 (10.4) years, and 3131 (50.2%) were female. In total, 2503
(41.0%) patients had a platelet count150x103, 2503 (40.5%) had ALT 60 IU/L, and
5765 (93.2%) had a high viral load. The numbers with genotype 1, 2, and 3 were 4291
(69.2%), 1838 (29.6%), and 76 (1.2%), respectively. Overall, 4434 (71.2%) patients were
treatment-naïve. SVR was achieved in 53.5% (95% CI: 51.1-55.9%) with alpha-2a and
61.6% (95% CI: 60.2-63.1%) with alpha-2b (p0.001). The dropout rate due to any AEs
was 10.3% (95%CI: 8.9-11.8%) and 9.3% (95%CI: 8.5-10.2%) for alpha-2a and alpha-2b,
respectively (p0.226). After adjustment for possible confounders, no differences
in effectiveness or tolerability were observed between the therapies, and the odds
ratio of alpha-2a for SVR was 0.97 (95% CI: 0.86-1.10), and its odds ratio for dropout
due to any AEs was 0.96 (95% CI: 0.79-1.17). There was no significant interaction of
genotype and therapy.CONCLUSIONS:Alpha-2a and alpha-2b in combination with
ribavirin showed comparable effectiveness and tolerability in clinical settings.
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OBJECTIVES: In addition to the pharmacological efficacy of infliximab therapy in
inflammatory bowel disease (IBD), it is also important to evaluate its impact on
other health outcomes, particularly in the rate of surgical interventions and hos-
pitalizations, which have high economic burden and are believed to represent a
marker of IBD severity. We aimed to estimate the impact of infliximab in these
outcomes in patients with IBD.METHODS: Systematic review and meta-analysis of
experimental (clinical trials) and observational studies comparing infliximab with
any other control group in IBD. Studies were identified by searching Medline and
Cochrane from inception to April 2012. Search results and studies characteristics
were assessed independently. Subgroup analyses were done according to IBD type:
Crohn disease (CD) and ulcerative colitis (UC). Pooled estimates were performed
separately for clinical trials and observational studies. Odds ratios (OR) and 95%
confidence intervals (CI) were derived by random-effects meta-analysis. Heteroge-
neity was assessed with I2 test. RESULTS: Nine trials and 9 observational studies
were included. Infliximab significantly decreased risk of gastrointestinal surgery in
experimental studies (OR 0.36; 95%CI: 0.18-0.71), both in DC (OR 0.25; 95%CI: 0.10-
0.63) and UC (OR 0:55; 95%CI: 0.40-0.76). In absolute terms, there was a 9% reduction
in the rate of surgery (95%CI: 1-19%). Observational studies also showed a reduced
risk of surgery, which was significant in the case of CD (OR 0.42; 95% CI: 0.22 to 0.78).
Infliximab significantly reduced the risk of hospitalization, both in experimental
(OR 0.48; 95%CI: 0.34-0.66) and observational (OR 0:38; 95%CI: 0.24-0.58) studies,
with a decrease of 9% in hospitalization rate (95%CI: 5-14%). Mean duration of
hospitalization was shorten by 4.2 days (95%CI: 1.9-6.5) in infliximab treated
patients. CONCLUSIONS: Based on the best available evidence, infliximab therapy
is associated with a reduced risk of gastrointestinal surgery and hospitalization
rates in patients with IBD.
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OBJECTIVES: To describe health outcomes, the course of treatment and the
demographic and clinical characteristics of HCV adult patients infected with
genotype 1 receiving interferon-alfaribavirin therapy in Poland. METHODS: A
retrospective analysis of anonymous data of patients treated in the HCV thera-
peutic programme of the National Health Fund was performed. Data was gath-
ered from three medical centres and included demographic and clinical char-
acteristics (sex, age, body weight, initial HCV RNA level, disease staging and
grading) as well as treatment course (first line/retreatment, posology, treatment
duration, outcomes and discontinuations). RESULTS: A total of 813 HCV geno-
type 1 adult patients’ records [586 treatment-naïve (N) and 227 treatment-expe-
rienced (E)] were included in the analysis. 55% were male (N: 53%, E: 60%), mean
age at the beginning of therapy was 48 (SD:13) years. Mean body weight was 68,0
(SD:11,8) kg in females and 82,4 (SD:12,3) kg in males. Mean initial HCV RNA was
5,9 (SD:0,8) log10IU/mL and 46% of patients had HCV RNA800 000 IU/mL. A total
of 85% records included data on disease staging (Sheuer 0-2: 67%; stage 3: 19%;
stage 4: 14%). 96% of patients received pegylated interferons (pegylated inter-
feron-alfa2a: 54%), 97% with ribavirin. A total of 15% of patients discontinued
therapy prematurely (N: 14%, E: 18%) after a mean of 6 months, and mean
treatment duration was 44 weeks for all patients. Overall SVR (sustained viral
response) was achieved in 42% of patients (N: 45%, E: 33%). Among treatment-
naïve patients not fully responding to therapy, 41% had relapse, 21% were par-
tial responders and 38% were null-responders. CONCLUSIONS: The real-life re-
sults of HCV genotype 1 treatment, with SVR rates below 50% in treatment naïve
patients, are unsatisfactory, especially when in Poland the prevalence of this
difficult-to-treat genotype is one of the most highest in Europe. Forthcoming
triple therapy with HCV protease inhibitors are promising and anticipated op-
tions for these patients.
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OBJECTIVES: This meta-analysis of randomized controlled trials was conducted to
evaluate the efficacy and incontinence rate of biomaterials (fibrin glue and fibrin
plug) in comparison to conservative and other interventional therapy in the treat-
ment of perianal fistula. METHODS: PubMed, Embase, Scopus, Google Scholar, and
Web of Science were searched for clinical trial studies investigated the effects of
biomaterials in the treatment of fistul in-ano. Clinical response and incontinence
were the key outcomes of interest. Data were searched from the time period of 1966
through June 2012. RESULTS: Eight randomized placebo-controlled clinical trials
that met our criteria (six comparing biomaterial with conservative treatment and
two with other interventions) were included in the analysis. Pooling of data showed
biomaterials effectiveness in comparison to other interventions was non signifi-
cant with relative risk (RR) of 1.23 (95% CI of 0.31-4.84, P 0.77). The RR for bioma-
terials comparing with conservative was non significant (RR 0.73 with 95% CI 
0.31-0.89, P 0.096). The incontinence rate RR in biomaterials and intervention was
also non significant with RR of 0.35 (95% CI  0.05-2.28, P  0.27). CONCLUSIONS:
This meta-analysis demonstrates that the effectiveness of biomaterials and con-
servative treatment was not different. The biomaterials in comparison to other
interventional therapies did not show any difference in regard to effectiveness and
also incontinence rate.
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OBJECTIVES: Symptoms of gastro-oesophageal reflux disease are estimated to
occur in 30-50% of pregnancies, with the incidence approaching 80% in some
populations. Indian studies have shown prevalence ranging upto 50 % . As with
many other conditions in pregnancy, medical therapy with pharmaceutical
agents is a concern, as the potential teratogenicity of medications is not well
known. Though prevalence numbers are high, many patients have mild and
infrequent symptoms, which often respond to lifestyle and dietary modifica-
tions. However, some patients report very severe symptoms of hyperacidity
affecting their Quality of Life which need treatment. The safety of H2 Receptor
antagonists and PPIs in pregnancy is not well established. Antacids could be a
good option as their systemic toxicity is low and safety profile is enhanced.
METHODS: Data has been collected from practicing gynaecologists in a hospital
located in Southern India . 50 female patients suffering from heartburn and/or
dyspepsia as symptoms of hyperacidity and GERD were treated with antacids
containing aluminium hydroxide, magnesium hydroxide and dimethicone. The
patients were prescribed antacids for atleast 7 days and the effectiveness and
safety profile of antacids was studied. The patients were followed up after one
week and the response along with adverse effects were documented. RESULTS:
The effectiveness was achieved in 85 % of women who took only antacids atleast
for 1 week. In 10 % of patients, Proton Pump Inhibitor was also added to achieve
the desired response. Apart from 2 cases of mild diarrhea, no other significant
side effects were noted. CONCLUSIONS: Antacids containing aluminium hy-
droxide , magnesium hydroxide and dimethicone can be a good therapy option
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